Recommended dose: 6 mg (0.05 mL) intravitreal inj every 4 wk (mthly) for the first 3 doses, then every 12 wk (3 mth) thereafter. May individualize treatment intervals based on disease activity as assessed by visual acuity &/or anatomical parameters. Treatment interval could be as frequent as every 8 wk (2 mth).
Discontinue use in patients w/ rhegmatogenous retinal detachment or stage 3 or 4 macular holes. Carefully evaluate patient's medical history for hypersensitivity reactions prior to procedure. Endophthalmitis & retinal detachment; retinal vasculitis &/or vascular occlusion; risk factors for retinal pigment epithelial tears. History of stroke, transient ischaemic attacks or MI w/in the last 3 mth. Monitor & manage IOP & optic nerve head perfusion. Bilateral treatment. Immunogenicity. Not to be administered concurrently w/ other anti-VEGF medicinal products (systemic or ocular). W/hold dose & do not resume earlier than the next scheduled treatment in the event of decrease in best corrected visual acuity (BCVA) of ≥30 letters compared w/ the last assessment of visual acuity; retinal break; subretinal haemorrhage involving the centre of the fovea, or, if the size of the haemorrhage is ≥50% of the total lesion area; performed or planned intraocular surgery w/in the previous or next 28 days. May experience temporary visual disturbances & should be advised not to drive or use machinery until visual function has recovered sufficiently. Females of reproductive potential should use effective contraception during treatment & for at least 1 mth after the last dose. Not to be used during pregnancy. Breastfeeding is not recommended during treatment & for at least 1 mth after the last dose. Ped patients (<18 yr).
Sign Out
